Novartis will purchase Nestlé’s
majority stake in the eye-care company Alcon
for $28.1 billion, raising its own stake to 77 percent. The drugmaker is
pushing further into the eye-care industry, where it hopes to capitalize on
Alcon’s surgical, pharmaceutical and consumer eye-care business lines, which
together reported $6.3 billion in sales in 2008. Novartis already sells contact
lenses and eye disease treatments and says that with the merger, the combined
company would have a product line covering 70 percent of the eye-care sector. The
purchase will be financed with capital reserves and debt issues, and Novartis
expects the deal to close in the second half of 2010, pending regulatory
approval.
More